- citati u SCIndeksu: [1]
- citati u CrossRef-u:[1]
- citati u Google Scholaru:[
 ]
- posete u poslednjih 30 dana:11
- preuzimanja u poslednjih 30 dana:5
|
|
|
2015, vol. 65, br. 1, str. 33-46
|
|
Farmakoekonomska evaluacija primene rastvora za infuziju kaspofungina i amfotericina B u terapiji teških sistemskih mikoza
A pharmacoeconomic evaluation of capsofungin and amphotericin B for intravenous infusion for treatment of systemic fungal infection
aMerck Sharp & Dohme d.o.o., (Airport City), Beograd - Novi Beograd bUniverzitet u Beogradu, Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo, Srbija cUniverzitet u Beogradu, Farmaceutski fakultet, Institut za medicinsku biohemiju, Srbija
e-adresa: lakic.dragana@pharmacy.bg.ac.rs
Projekat: Interaktivna uloga dislipidemije, oksidativnog stresa i inflamacije u aterosklerozi i drugim bolestima: genetički i biohemijski markeri (MPNTR - 175035)
Interakcije ksenobiotika i uticaj na sisteme u biomedicini (MPNTR - 41012)
Sažetak
Empirijska primena antimikotika u terapiji invazivnih gljivičnih infekcija (IGI) u febrilnoj neutropeniji predstavlja značajan trošak, ali je neophodna kod pacijenata sa leukemijom i nakon transplantacije matičnih ćelija hematopoeze. Brojne kliničke studije pokazale su male razlike u efikasnosti amfotericina B i kaspofungina u empirijskoj terapiji IGI, ali to ne oslikava u pravoj meri odnos trošak-efektivnost. Cilj rada je bio poređenje isplativosti kaspofungina i amfotericina B lipidni kompleks (ABLC) u empirijskoj antigljivičnoj terapiji kod pacijenata sa febrilnom neutropenijom kroz model-drvo odlučivanja, a iz perspektive Republičkog fonda za zdravstveno osiguranje (RFZO). Primenjena je analiza isplativosti, (cost-effectiveness analsys - CEA), za period od 14 dana terapije. U modelu su kombinovani podaci o efikasnosti iz randomizovanih kliničkih studija, dok su troškovi uzeti iz važećeg cenovnika zdravstvenih usluga i Liste lekova RFZO. Ukupan trošak po dodatno izlečenoj gljivičnoj infekciji za kaspofungin iznosi 639.750,06 RSD, dok je za ABLC 2.153.403,61 RSD. U analizi osetljivosti, primenom različite telesne težine pacijenata (50kg ili 70kg) i različite doze ABLC, kaspofungin je ponovo bio isplativija strategija empirijske antigljivične terapije. Kaspofungin, pored boljeg bezbednosnog profila je i troškovno isplativiji od ABLC. Ovu činjenicu bi trebalo imati u vidu prilikom odabira terapije za lečenje IGI kod pacijenata sa febrilnom neutropenijom.
Abstract
Empirical application of antifungal drugs in the treatment of invasive fungal infections (IFI) in febrile neutropenia represent significant cost, but it is essential in patients with leukemia and after hematopoietic stem cell transplantation. Numerous clinical studies have shown little difference in the efficacy of amphotericin B and caspofungin in IFI empirical therapy, but it does not reflect their cost-effectiveness. The aim of this study was to compare the costeffectiveness of caspofungin and amphotericin B lipid complex (ABLC) in the empirical antifungal therapy in patients with febrile neutropenia using model-decision tree, from the perspective of the National Health Insurance Fund (NHIF). We used the cost-effectiveness analysis, for a period of 14 days of therapy. In model we combined data on efficacy from randomized clinical trials, while the costs were taken from the Drug list or service fee NHIF. The total cost per additional cured fungal infection with caspofungin was 639,750.06 RSD, while with ABLC was 2,153,403.61 RSD. In the sensitivity analysis, using different weights of patients (50kg or 70kg) and different doses of ABLC, caspofungin was again most cost-effective strategy for empirical antifungal therapy. Caspofungin, in addition to a better safety profile, is more cost-efficient than ABLC. This fact should be kept in mind when choosing a therapy for the treatment of IFI in patients with febrile neutropenia.
|
|
|
|
Reference
|
|
|
*** (2014) Lista lekova koji se propisuju i izdaju na teret obaveznog zdravstvenog osiguranja. Službeni glasnik, br. 123
|
|
|
*** (2014) Pravilnik o cenama zdravstvenih usluga na sekundarnom i tercijarnom nivou zdravstvene zaštite. Službeni glasnik, br. 37
|
|
  
|
Al-Badriyeh, D., Liew, D., Stewart, K., Kong, D.C.M. (2009) Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. Journal of Antimicrobial Chemotherapy, 63(6): 1276-1285
|
|
|
Bruynesteyn, K., Gant, V., McKenzie, C., Pagliuca, T., Poynton, C., Kumar, R.N., Jansen, J.P. (2007) A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. European Journal of Haematology, 78(6): 532-539
|
|
|
Clemons, K.V., Stevens, D.A. (2004) Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrobial agents and chemotherapy, 48(3): 1047-50
|
|
3
|
Drummond, M.F., Sculpher, M.J., Torrence, G.W., OBrien, B.J., Stoddart, G.L. (2005) Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press
|
|
|
Ibrahim, A.S., Gebremariam, T., Husseiny, M.I., Stevens, D.A., Fu, Y., Edwards, J.E., Spellberg, B. (2008) Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis. Antimicrobial Agents and Chemotherapy, 52(4): 1573-1576
|
|
|
Maertens, J., Marchetti, O., Herbrecht, R., Cornely, O.A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W.J., Lass-Flörl, C., Ribaud, P., Thiebaut, A., Cordonnier, C. (2010) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. Bone Marrow Transplantation, 46(5): 709-718
|
|
|
Marisavljević, D. (2013) Klinička hematologija. Beograd: Zavod za udžbenike, p. 1046-52
|
|
|
Martino, R. (2004) Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Current medical research and opinion, 20(4): 485-504
|
|
|
Naik, S., Lundberg, J., Kumar, R., Sjolin, J., Jansen, J.P. (2011) Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scandinavian Journal of Infectious Diseases, 43(6-7): 504-514
|
|
|
Pappas, Peter G., Kauffman, Carol A., Andes, D., Benjamin, Daniel K., ***, Calandra, Thierry F., Edwards, John E., ***, Filler, Scott G., Fisher, John F., Kullberg, B., Ostrosky‐Zeichner, L., Reboli, Annette C., Rex, John H., Walsh, Thomas J., Sobel, Jack D. (2009) Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 48(5): 503-535
|
|
|
Stam, W.B., Aversa, F., Kumar, R.N., Jansen, J.P. (2008) Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. Value in Health, 11(5): 830-841
|
|
|
Svetska zdravstvena organizacija (2014) CHOosing Interventions that are Cost Effective (WHOCHOICE). http://www.who.int/choice/costs/CER_thresholds/en
|
|
|
Turner, S.J., Chen, S.C., Slavin, M.A., Kong, D.C. (2013) Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients. Expert Review of Pharmacoeconomics & Outcomes Research, 13(2): 227-235
|
|
1
|
Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., Morrison, V.A., Segal, B.H., Steinbach, W.J., Stevens, D.A., Burik, J.A., Wingard, J.R., Patterson, T.F. (2008) Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 46(3): 327-360
|
|
|
Walsh, T.J., Teppler, H., Donowitz, G.R., Maertens, J.A., Baden, L.R., Dmoszynska, A., Cornely, O.A., Bourque, M.R., Lupinacci, R.J., Sable, C.A., dePauw Ben, E. (2004) Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. New England Journal of Medicine, 351(14): 1391-1402
|
|
|
Wingard, J.R., White, M.H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., Group, L.A. (2000) A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia. Clinical Infectious Diseases, 31(5): 1155-1163
|
|
|
|
|